Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Prepaid Assets (2020 - 2025)

Barinthus Biotherapeutics' Prepaid Assets history spans 6 years, with the latest figure at $4.8 million for Q4 2025.

  • For Q4 2025, Prepaid Assets fell 22.13% year-over-year to $4.8 million; the TTM value through Dec 2025 reached $4.8 million, down 22.13%, while the annual FY2025 figure was $4.8 million, 22.13% down from the prior year.
  • Prepaid Assets reached $4.8 million in Q4 2025 per BRNS's latest filing, down from $6.3 million in the prior quarter.
  • In the past five years, Prepaid Assets ranged from a high of $11.7 million in Q2 2022 to a low of $6000.0 in Q2 2021.
  • Average Prepaid Assets over 5 years is $4.3 million, with a median of $4.0 million recorded in 2021.
  • Peak YoY movement for Prepaid Assets: surged 194883.33% in 2022, then plummeted 94.54% in 2025.
  • A 5-year view of Prepaid Assets shows it stood at $995000.0 in 2021, then plummeted by 38.59% to $611000.0 in 2022, then surged by 1521.44% to $9.9 million in 2023, then plummeted by 37.39% to $6.2 million in 2024, then dropped by 22.13% to $4.8 million in 2025.
  • Per Business Quant, the three most recent readings for BRNS's Prepaid Assets are $4.8 million (Q4 2025), $6.3 million (Q3 2025), and $854000.0 (Q2 2025).